Interstitial lung disease: perhaps unclassifiable, but not untreatable
- 1 February 2020
- journal article
- editorial
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 8 (2) , 126-127
Abstract
No abstract availableFunding Information
- National Institutes of Health
This publication has 9 references indexed in Scilit:
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung DiseaseNew England Journal of Medicine, 2019
- Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-AnalysisAnnals of the American Thoracic Society, 2018
- A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group PerspectiveAmerican Journal of Respiratory and Critical Care Medicine, 2017
- Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity PneumonitisChest, 2017
- Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2016
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung DiseaseThe Journal of Rheumatology, 2013
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012